콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

H-001

Supelco

Hydrochlorothiazide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C7H8ClN3O4S2
CAS Number:
Molecular Weight:
297.74
EC Number:
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

certified reference material

형태

liquid

특징

Snap-N-Spike®/Snap-N-Shoot®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

농도

1.0 mg/mL in methanol

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

clinical testing

형식

single component solution

저장 온도

−20°C

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

유전자 정보

human ... SLC12A3(6559)

일반 설명

Hydrochlorothiazide is a calcium-sparing diuretic used for treatment of edema and hypertension. A thiazide derivative, hydrochlorothiazide is sold under the trade names Microzide® and Aquazide H. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

픽토그램

FlameSkull and crossbonesHealth hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
Alexander V Murray et al.
Journal of clinical hypertension (Greenwich, Conn.), 14(12), 821-827 (2012-12-05)
Combination antihypertensive therapies are recommended to attain blood pressure (BP) targets especially in high-risk patients in whom rapid and pronounced BP control is essential. This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination
Yoshihisa Hanayama et al.
Acta medica Okayama, 66(6), 449-459 (2012-12-21)
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone. This study examined the practical efficacy of a combination therapy
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
Successful rapid desensitization to hydrochlorothiazide.
Jamma Li et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 110(4), 307-308 (2013-03-29)

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.